Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Incyte
Company Monitoring Page for Incyte
latest headlines for company on cafepharma
Incyte the latest to fall victim to JAK scrutiny as FDA pushes back Jakafi review in GVHD
Fierce Pharma
Tue, 06/8/21 - 09:42 pm
Tags:
Incyte
,
FDA
,
JAK inhibitors
ASCO 2021: Watch for Sanofi/Sloan Kettering, Incyte, Exelixis and AstraZeneca
BioSpace
Thu, 05/20/21 - 12:35 pm
Tags:
ASCO 2021
,
Sanofi
,
Sloane Kettering
,
Incyte
,
AstraZeneca
,
Exelixis
,
oncology
Incyte’s Ruxolitinib Cream Shows Promise for Vitiligo in Phase III Trials Published: May 17, 2021 By Brandon May
BioSpace
Mon, 05/17/21 - 11:02 pm
Tags:
Incyte
,
ruxolitinib
,
vitiligo
,
clinical trials
Incyte’s PD-(L)1 inhibitor headed for an ODAC showdown next month
Endpoints
Thu, 05/13/21 - 12:06 pm
Tags:
Incyte
,
FDA
,
ODAC
,
anal cancer
,
retifanlimab
Incyte to pay $12.6 million to resolve drug charity kickback claims
Reuters
Fri, 05/7/21 - 10:54 am
Tags:
Incyte
,
Jakafi
,
kickbacks
,
Medicare
Lilly claims promising finding in failed study of COVID-19 drug
BioPharma Dive
Thu, 04/8/21 - 07:40 pm
Tags:
Eli Lilly
,
Incyte
,
COVID-19
,
baricitinib
Incyte Drug Misses Endpoint in COVID-Respiratory-Distress Trial
TheStreet.com
Sun, 03/21/21 - 11:50 pm
Tags:
Incyte
,
Jakafi
,
clinical trials
,
COVID-19
,
ARDS
Jakafi failed the primary endpoint in a Covid-19 study. But Incyte is still going to FDA with a compassionate use pitch
Endpoints
Fri, 03/19/21 - 10:49 am
Tags:
Jakafi
,
Incyte
,
COVID-19
,
clinical trials
Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment
NASDAQ
Wed, 03/3/21 - 10:53 am
Tags:
Eli Lilly
,
Incyte
,
baricitinib
,
alopecia areata
FDA to quickly review Incyte’s Jakafi in chronic GVHD
Pharmaforum
Tue, 02/23/21 - 10:42 am
Tags:
FDA
,
Incyte
,
Jakafi
,
graft vs host disease
Incyte Says FDA Grants Priority Review For Eczema Cream
Yahoo/SmarterAnalyst
Mon, 02/22/21 - 11:00 am
Tags:
Incyte
,
eczema
,
FDA
,
priority review
,
ruxolitinib
What's Behind Incyte's Better-Than-Expected Q4 Earnings
Motley Fool
Tue, 02/9/21 - 11:57 pm
Tags:
Incyte
,
earnings
Incyte makes bid to join the checkpoint inhibitor club
Pharmaforum
Tue, 02/2/21 - 10:25 am
Tags:
Incyte
,
FDA
,
retifanlimab
,
anal cancer
,
HIV
,
HPV
Incyte lands priority review for PD-1 inhibitor in anal cancer
Fierce Biotech
Fri, 01/22/21 - 10:31 am
Tags:
Incyte
,
FDA
,
priority review
,
anal cancer
,
retifanlimab
JPM: Established relationships were key to pandemic drug launches, Incyte CEO says
Fierce Pharma
Sat, 01/16/21 - 11:48 pm
Tags:
COVID-19
,
pandemic
,
drug launches
,
Incyte
,
JPMHC 2021
Novartis/Incyte draw blank with Jakafi in COVID-19
Pharmaforum
Mon, 12/14/20 - 10:35 am
Tags:
Novartis
,
Incyte
,
Jakafi
,
COVID-19
,
clinical trials
EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis
Yahoo
Sun, 11/1/20 - 01:37 pm
Tags:
Eli Lilly
,
Incyte
,
baricitinib
,
atopic dermatitis
,
EADV
Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time
Marketwatch
Mon, 09/14/20 - 10:21 am
Tags:
Eli Lilly
,
Incyte
,
olumiant
,
COVID-19
,
remdesivir
,
Gilead Sciences
Karuna and Incyte scrap programs; More cash for the SPACs
Endpoints
Wed, 08/5/20 - 12:02 am
Tags:
Karuna Therapeutics
,
Eli Lilly
,
Incyte
,
SPAC
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
MedCity News
Mon, 08/3/20 - 10:14 am
Tags:
FDA
,
Monjuvi
,
CAR-T
,
MorphoSys
,
Incyte
,
diffuse large B-cell lymphoma
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
cafepharma is a: rock, tree, site
*
Fill in the blank.